Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Aerospace
GE
|
+$2.22B |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$2.02B |
| 3 |
Amazon
AMZN
|
+$1.98B |
| 4 |
EPAM Systems
EPAM
|
+$1.88B |
| 5 |
Apple
AAPL
|
+$1.57B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$3.27B |
| 2 |
Netflix
NFLX
|
+$2.99B |
| 3 |
Microsoft
MSFT
|
+$1.94B |
| 4 |
Home Depot
HD
|
+$1.69B |
| 5 |
CSX Corp
CSX
|
+$1.11B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.08% |
| 2 | Healthcare | 14.23% |
| 3 | Consumer Discretionary | 12.89% |
| 4 | Financials | 10.35% |
| 5 | Industrials | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Globus Medical
GMED
$11.4B
| $140M | 0.03% |
1,901,114
| – | – |
|
277
British American Tobacco
BTI
$124B
| $139M | 0.03% |
3,303,960
+3,393
| +0.1% | +$145K |
|
278
CubeSmart
CUBE
$9.4B
| $137M | 0.03% |
+2,633,537
| New | +$133M |
|
279
Leslie's
LESL
$7.11M
| $136M | 0.03% |
350,472
+180,621
| +106% | +$75.1M |
|
|
LNW
280
DELISTED
Light & Wonder
LNW
| $135M | 0.03% |
2,303,862
+75,926
| +3% | +$4.59M |
|
281
ResMed
RMD
$32.6B
| $135M | 0.03% |
557,558
+253,121
| +83% | +$61.2M |
|
282
Extreme Networks
EXTR
$3.21B
| $135M | 0.03% |
11,055,375
+2,141,000
| +24% | +$26.7M |
|
283
Paylocity
PCTY
$7.7B
| $133M | 0.03% |
647,968
-3,889
| -0.6% | -$787K |
|
|
GTM
284
ZoomInfo Technologies
GTM
$1.11B
| $131M | 0.03% |
2,189,493
-1,127,856
| -34% | -$60.5M |
|
285
ExxonMobil
XOM
$654B
| $127M | 0.03% |
1,539,638
-3,192,728
| -67% | -$248M |
|
|
VGR
286
DELISTED
Vector Group Ltd.
VGR
| $126M | 0.03% |
10,423,654
-94,263
| -0.9% | -$1.05M |
|
287
Credo Technology Group
CRDO
$51.9B
| $125M | 0.03% |
+8,750,082
| New | +$127M |
|
288
Asbury Automotive
ABG
$3.76B
| $122M | 0.03% |
761,102
+198,985
| +35% | +$34.8M |
|
289
PAR Technology
PAR
$744M
| $120M | 0.03% |
2,977,672
-114,789
| -4% | -$4.7M |
|
|
GDEN
290
DELISTED
Golden Entertainment
GDEN
| $120M | 0.03% |
2,066,100
+441,100
| +27% | +$22.6M |
|
291
Equifax
EFX
$21.3B
| $120M | 0.03% |
504,697
-930,611
| -65% | -$219M |
|
292
Chubb
CB
$133B
| $119M | 0.03% |
557,114
+1,341
| +0.2% | +$273K |
|
293
LPL Financial
LPLA
$29.4B
| $117M | 0.03% |
+641,467
| New | +$112M |
|
294
Vicor
VICR
$10.6B
| $115M | 0.03% |
1,625,517
+563,884
| +53% | +$50.6M |
|
295
TPG
TPG
$8.35B
| $114M | 0.03% |
+3,789,938
| New | +$117M |
|
296
Perimeter Solutions
PRM
$5.67B
| $112M | 0.03% |
9,260,505
| – | – |
|
|
AVDX
297
DELISTED
AvidXchange
AVDX
| $111M | 0.03% |
13,838,867
-854,651
| -6% | -$8.62M |
|
298
Dole
DOLE
$1.26B
| $109M | 0.03% |
8,788,583
+4,206,200
| +92% | +$58.2M |
|
299
Intel
INTC
$530B
| $107M | 0.03% |
+2,160,359
| New | +$107M |
|
|
CCC
300
CCC Intelligent Solutions
CCC
$4B
| $107M | 0.03% |
9,681,908
-1,647,308
| -15% | -$17.3M |
|
Similar funds
Capital Research Global Investors's Q1 2022 Portfolio in Review
As of Q1 2022, Capital Research Global Investors held 468 positions worth $405B, down 11% from $453B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Capital Research Global Investors's Q1 2022 filing shows 28 new, 180 increased, 190 reduced and 28 closed positions. Its largest new stake was Halliburton: 17,891,897 shares worth $678M. The largest sale was Gilead Sciences, an estimated $3.27B.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Capital Research Global Investors's largest Q1 2022 buy was Halliburton: 17,891,897 shares worth $678M.
- Capital Research Global Investors added most to GE Aerospace in Q1 2022, an estimated $2.22B increase.
- Capital Research Global Investors's biggest Q1 2022 reduction was Gilead Sciences, cutting an estimated $3.27B.
- Capital Research Global Investors fully exited PayPal in Q1 2022, selling an estimated $769M.
- Capital Research Global Investors's ten largest holdings make up 28% of its $405B portfolio in Q1 2022.
- Capital Research Global Investors opened 28 new positions and closed 28 in Q1 2022.
- Capital Research Global Investors's portfolio value fell 11% quarter-over-quarter to $405B.
Based on Capital Research Global Investors's 13F filing for Q1 2022, filed 16 May 2022.